Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2011 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 19 February 2002, orphan designation (EU/3/02/088) was granted by the European Commission to Pharmax Limited, United Kingdom, for colistimethate sodium for the treatment of Pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosis.

Pharmax Limited changed its name to Forest Laboratories UK Ltd in July 2002.

Key facts

Active substance
Colistimethate sodium
Disease / condition
Treatment of Pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosis
Date of first decision
EU designation number

Sponsor's contact details

Forest Laboratories UK Ltd
Riverbridge House
Crossways Business Park
Kent DA2 6SL
United Kingdom
Telephone: +44 1322 421800
Telefax: +44 1332 291306

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating